【结 构 式】 |
【药物名称】Teroxirone, NSC-296934, alpha-TGT, alpha-TGI 【化学名称】[1(R*),3(R*),5(S*)]-(±)-1,3,5-Tris(oxiranylmethyl)-1,3,5-triazine-2,4,6(1H,3H,5H)-trione 【CA登记号】59653-73-5, 59653-74-6 (beta-isomer) 【 分 子 式 】C12H15N3O6 【 分 子 量 】297.26985 |
【开发单位】Henkel (Originator), National Cancer Institute (Originator), Asta Medica (Licensee) 【药理作用】Oncolytic Drugs |
合成路线1
The compound can be prepared in the following way: The reaction of a large excess of epichlorohydrin (II) with cyanuric acid (I) at a temperature above 60 C leads to the 1,3,5-tris(oxiranylmethyl)-substituted derivative (III). Thus, epichlorohydrin functions both as alkylating agent and base. The addition of sodium hydroxide accelerates and completes the hydrogen chloride abstraction after the first step of the reaction. Fractional crystallization of the product gives the alpha and beta stereoisomers.
【1】 Budnowski, M.; Preparation and properties of the diastereoisomeic 1,3,5-triglycidyl-s-triazinetriones. Angew Chem 1968, 7, 827. |
【2】 Schnegelberger, H.; Budnowski, M. (Henkel KgA); Therapeutic compsns. with a cytostatic action. GB 2044614 . |
【3】 Castaner, J.; Serradell, M.N.; Blancafort, P.; Teroxirone. Drugs Fut 1983, 8, 11, 936. |